rs140597 — FBN1 D1113G

FBN1 Asp1113Gly — A Missing Anchor in the Aortic Wall

The aorta tolerates tens of millions of pressure pulses over a lifetime because its wall is reinforced by an elastic scaffold made of microfibrils¹¹ microfibrils
rope-like extracellular matrix structures assembled from fibrillin-1 molecules linked end-to-end, providing elasticity and tensile strength throughout connective tissue. Fibrillin-1 is a 2,871-amino-acid glycoprotein encoded by FBN1 on chromosome 15. It contains 47 epidermal growth factor-like (EGF-like) domains, 43 of which are calcium-binding (cbEGF). Each cbEGF domain requires calcium to fold into a rigid rod — calcium ions are not just incidental cofactors but the structural glue that holds the entire module together. Aspartate residues at conserved positions within these domains directly coordinate the calcium ion, and substituting any one of them disrupts the fold.

The p.Asp1113Gly variant (coding-strand c.3338A>G on the minus-strand FBN1 transcript; plus-strand T→C at chr15:48,487,437) removes the calcium-coordinating aspartate at position 1113 and replaces it with glycine — the smallest amino acid, with no side chain at all. ClinVar classifies this variant as Pathogenic or Likely Pathogenic across three independent submissions (RCV000663632, RCV000802396, RCV002284420), with conditions listed as Marfan syndrome and familial thoracic aortic aneurysm and aortic dissection (FTAAD). The global allele frequency of the C allele is approximately 0.02% (20 of 88,940 ALFA samples), consistent with a rare, high-penetrance disease variant under negative selection.

The Mechanism

Within a cbEGF domain, a conserved sequence motif coordinates a single calcium ion through the side chains of several residues — aspartate residues contribute critically to this coordination shell. Disrupting calcium coordination destabilizes the cbEGF fold²² Disrupting calcium coordination destabilizes the cbEGF fold
Dietz et al. 1993 showed that all early Marfan syndrome missense mutations at that time affected residues with calcium-binding significance in EGF-like domains, preventing fibrillin-1 from achieving the extended rigid conformation needed for microfibril polymerization. The misfolded monomer acts through a dominant-negative mechanism³³ dominant-negative mechanism
the defective protein physically interferes with normal fibrillin-1 assembly, impairing the entire microfibril network even when the second FBN1 allele is intact — which is why a single copy of this variant is sufficient to cause disease.

Weakened microfibrils in the aortic media reduce mechanical resilience of the aortic wall and, importantly, fail to sequester transforming growth factor-beta (TGF-β) in the extracellular matrix. Excess free TGF-β drives smooth muscle cell dysfunction, progressive aortic wall stiffening, and aneurysmal dilation at the sinuses of Valsalva — the anatomical pinch-point where nearly all Marfan-related dissections originate.

The Evidence

The broader clinical evidence base for FBN1 cbEGF domain missense variants predicting aortic disease is well-established:

Tan et al. (Human Molecular Genetics, 2017)⁴⁴ Tan et al. (Human Molecular Genetics, 2017) sequenced FBN1 in 687 patients with sporadic non-syndromic aortic dissection and found pathogenic FBN1 variants in 3.9% (27 patients), the majority being missense mutations — demonstrating that FBN1 pathogenic variants cause FTAAD even in the absence of full syndromic Marfan features.

The most important prognostic data for FBN1 pathogenic variant carriers come from Milleron et al. (JACC, 2020)⁵⁵ Milleron et al. (JACC, 2020): 954 patients with FBN1 pathogenic variants followed over 8,594 patient-years showed that type A aortic dissection occurred at only 0.4 events per 1,000 patient-years when maximum aortic diameter remained below 50 mm on guideline-directed treatment. This is a critically important number: risk is not inevitable but is profoundly modifiable by structured surveillance and timely intervention.

On treatment, Brooke et al. (NEJM, 2008)⁶⁶ Brooke et al. (NEJM, 2008) showed that losartan (an angiotensin receptor blocker that blocks TGF-β pathway overactivation) reduced aortic root dilation rate from 3.54 mm/yr to 0.46 mm/yr in 18 pediatric Marfan patients — approximately an 87% reduction. This finding underpins current guidelines recommending ARBs when aortic root dilation progresses faster than 5 mm/year or root diameter exceeds 40 mm in children.

Practical Actions

The cornerstone of management is annual transthoracic echocardiography to track aortic root diameter at the sinuses of Valsalva. Medical therapy with a beta-blocker (to reduce heart rate and aortic wall stress) or ARB (losartan, to block excess TGF-β signaling) should be initiated at diagnosis or upon detecting progressive dilation. Prophylactic aortic root replacement is recommended when the aortic root approaches 5.0 cm in adults (4.5–5.0 cm in rapid progressors or patients with a family history of dissection).

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin) inhibit lysyl oxidase — the enzyme that cross-links collagen and elastin — and carry an FDA black-box warning for aortic aneurysm rupture and dissection risk, particularly in patients with connective tissue disorders. All prescribers must be informed of this contraindication.

Strenuous isometric exercise (heavy weightlifting, contact sports, competitive athletics) should be avoided — these modalities generate abrupt spikes in arterial pressure that place disproportionate mechanical stress on an already vulnerable aortic wall.

Cascade genetic testing of first-degree relatives is clinically essential. A single positive finding in one family member should trigger testing of all parents, siblings, and adult children, since autosomal dominant transmission gives each relative a 50% chance of carrying the variant — and several may harbor silent aortic dilation detectable only by imaging.

Interactions

FBN1 pathogenic variants, including D1113G, interact clinically with variants in TGF-β pathway genes (TGFBR1, TGFBR2, SMAD2, SMAD3) — the genetic basis of Loeys-Dietz syndrome. Carriers who also harbor pathogenic variants in ACTA2 (smooth muscle alpha-actin) or MYH11 (smooth muscle myosin heavy chain), both associated with independent familial TAAD syndromes, may warrant more aggressive surveillance thresholds, though formal compound genotype data for D1113G specifically are not published.

Other FBN1 cbEGF domain missense variants in the database — including rs193922239 (p.Gly2627Arg) — share the same dominant-negative mechanism and clinical management protocol. The diagnosis of Marfan syndrome versus FTAAD-without-full-Marfan-features depends on the presence of ocular and skeletal manifestations alongside the cardiovascular findings; either presentation requires the same aortic surveillance program.